|
?:authorAffiliation
|
-
[\'Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20871, USA.\', \'Emergency Medical Center, Fujisawa City Hospital 2-6-1 Fujisawa, Fujisawa City, Kanagawa 251-8550, Japan.\', \'Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.\', \'Pulmonary Division, Department of Internal Medicine, Saiseikai Utsunomiya Hospital 911-1 Takebayashimachi, Utsunomiya 321-0974, Japan.\', \'Department of Emergency & Intensive care, Saiseikai Utsunomiya Hospital 911-1 Takebayashimachi, Utsunomiya 321-0974, Japan.\', \'Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.\', \'Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA.\', \'Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20871, USA. surender.khurana@fda.hhs.gov.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}